Methylone

PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions. Transcend will operate as a wholly owned subsidiary of Otsuka America, Inc. Under the terms of the agreement, Otsuka paid $700 million to Transcend shareholders at closing, with up to $525 million in additional contingent consideration based on future sales related to assets in development. “This marks an important step forward in our continued commitment to patients and their families in need of more treatment options for serious mental illness,” said Tarek Rabah, president and CEO, Otsuka North America Pharmaceutical Business. “By combining Otsuka’s decades of expertise in central nervous system disorders with Transcend’s pioneering approach, we are well positioned to accelerate the development of new treatment options for those who continue to face significant unmet needs.” Transcend’s lead investigational candidate, TSND-201 (methylone), is a rapid-acting neuroplastogen being developed as a potential treatment for PTSD. In the United States, more than 13 million individuals are estimated to be affected by PTSD each year, yet no new treatments have been approved for more than 25 years, underscoring a large unmet need. TSND-201 demonstrated favorable results in a Phase 2 clinical trial (IMPACT-1), and a Phase 3 trial is currently underway to further evaluate its safety and efficacy. The therapy has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and was selected as part of the priority voucher program to accelerate access to psychedelic treatments. “Joining Otsuka marks an exciting new chapter for Transcend and the patients we aim to serve,” said Blake Mandell, CEO of Transcend. “Otsuka’s scientific rigor, global scale, and long-standing commitment to advancing mental health innovation will help accelerate our efforts to develop transformative therapies and expand access to new treatment options for the people who need it most.” This acquisition builds on Otsuka’s longstanding leadership in central nervous system disorders and commitment to advancing treatment options for patients living with serious neuropsychiatric conditions like PTSD. By integrating Transcend’s innovative approach, Otsuka aims to continue advancing scientifically rigorous therapies that deliver safe, effective, and accessible options that meaningfully improve patient outcomes. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. About Transcend Therapeutics Transcend, founded in 2021 and based in New York City, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. The company's mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Visit http://www.transcendtherapeutics.com for more information.

Otsuka Pharmaceutical has completed its acquisition of Transcend Therapeutics, with New York-based Transcend now a wholly owned subsidiary of Otsuka America, Inc., the US arm of Japan-based Otsuka Pharmaceutical Co., Ltd. The deal, originally announced in March 2026, positions Otsuka to advance TSND-201 (methylone), a Phase III-stage neuroplastogen for post-traumatic stress disorder, through a therapeutic area where no new FDA-approved treatments have emerged in over two decades. The transaction was structured as a full corporate acquisition, with Otsuka America paying USD 700 million upfront and Transcend shareholders eligible for up to USD 525 million in contingent commercial sales milestone payments, bringing total potential consideration to USD 1.225 billion. No individual milestone tiers were disclosed. Because the deal is a whole-company acquisition rather than a territorial license, Otsuka obtains worldwide, unrestricted rights to Transcend’s entire portfolio across all indications. Closing conditions have now been satisfied. TSND-201 is classified as a rapid-acting neuroplastogen — an agent designed to induce rapid and durable neural plasticity through action on monoamine transporters for serotonin, norepinephrine, and dopamine. Critically, the compound has no activity at the serotonin 5-HT2A receptor, which mediates hallucinogenic effects, distinguishing it from classical psychedelics such as psilocybin and from MDMA-based approaches currently in development. This non-hallucinogenic profile is clinically significant: it may eliminate the need for the extended supervised psychotherapy sessions that characterize psychedelic-assisted therapy models, simplifying administration and potentially broadening patient access. In the Phase II IMPACT-1 trial — a randomized, double-blind, placebo-controlled study enrolling 65 adults with severe PTSD across 16 sites — TSND-201 demonstrated a statistically significant placebo-adjusted improvement in CAPS-5 total severity scores of −9.64 points at Day 64 (p \= 0.011), with statistically significant separation from placebo observed as early as Day 10. Results were published in JAMA Psychiatry. The US FDA granted TSND-201 Breakthrough Therapy Designation in July 2025, and the program subsequently received an FDA Commissioner’s National Priority Voucher. A Phase III trial for PTSD is currently ongoing. For Otsuka, the acquisition consolidates a strategic bet on rapid-acting CNS mechanisms at a time when the psychiatric drug development field is actively seeking alternatives to slow-onset antidepressant and anxiolytic classes. The company has operated in psychiatric and neurological fields since the 1970s and previously expanded its CNS pipeline through the acquisition of Mindset Pharma, which contributed serotonin 5-HT2A agonist discovery technology. TSND-201’s non-hallucinogenic, monoamine-based profile complements rather than overlaps with that existing portfolio, providing differentiated coverage across multiple pharmacological approaches to psychiatric disease. Transcend was founded in 2021 and had raised approximately USD 50 million prior to the transaction. The company is also advancing novel prodrugs of TSND-201, classified as new chemical entities, intended to further optimize the compound’s efficacy, safety, and tolerability profile. A development candidate has been selected and is undergoing non-clinical studies in preparation for an Investigational New Drug application to the FDA — providing Otsuka with potential pipeline optionality beyond the current Phase III program. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.